earnings
Revenue Surge and Pipeline Wins: Core Operating Leverage Expands (AZN Q1 2026 Earnings Call)
AstraZeneca delivered a strong start to the year, propelled by double-digit growth in its oncology and rare disease segments alongside positive high-level readouts from four major Phase III clinical programs.